Synaptogenix announces changes to scientific advisory board in preparation for phase 2 data

Conference call to be held tuesday, july 26th at 4:30pm et new york , july 26, 2022 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("the company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced changes to its scientific advisory board (sab) in preparation for phase 2 data from its phase 2b clinical trial of bryostatin-1 for patients suffering from advanced and moderately severe alzheimer's disease (ad).  the sab is comprised of industry and academic leaders in science and drug development and will be instrumental in the further development of the company's regenerative therapies across ad, fragile x syndrome, and multiple sclerosis (ms).
SNPX Ratings Summary
SNPX Quant Ranking